Belapectin is a polysaccharide commercialized by Galectin Therapeutics, with a leading Phase III program in Non-Alcoholic Steatohepatitis (NASH). According to Globaldata, it is involved in 12 clinical trials, of which 9 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Belapectin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Belapectin is expected to reach an annual total of $224 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Belapectin (GR-MD-02) is under development for the treatment of NASH with advanced fibrosis, liver fibrosis and decompensated liver cirrhosis, kidney fibrosis, cardiovascular fibrosis, pulmonary arterial hypertension, arrhythmias, metastatic melanoma, lung fibrosis, prostate cancer, sarcomas, breast cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer and portal hypertension. It is administered through intravenous route and targets galectin-3. It is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. The drug candidate is developed based on the carbohydrate technology. It is a new chemical entity. It was also under development for the treatment of diabetic nephropathy, moderate to severe plaque psoriasis and severe atopic dermatitis.
Galectin Therapeutics Overview
Galectin Therapeutics is a biotechnology company. The company products includes for fibrosis, cancer immunotherapy, plaque psoriasis, and oral galectin-3 inhibitors. It discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics also offer products such as GR-MD-02, GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. Its GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. Galectin The company provides research, study of science of galectin proteins. Its products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.
The operating loss of the company was US$30.2 million in FY2021, compared to an operating loss of US$23.4 million in FY2020. The net loss of the company was US$30.5 million in FY2021, compared to a net loss of US$23.5 million in FY2020.
For a complete picture of Belapectin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.